CartiHeal Receives FDA “Breakthrough Device Designation” for the novel Agili-C Implant

FDA’s Breakthrough Device Program is reserved for certain medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. This program is intended to help patients receive more timely access to these medical devices by expediting their development, assessment and review by FDA. You can read more here.